Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Top Cited Papers
Open Access
- 11 March 2010
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 362 (10) , 906-916
- https://doi.org/10.1056/nejmoa0905633
Abstract
Dyslipidemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Thyroid hormone lowers levels of serum low-density lipoprotein (LDL) cholesterol and has other potentially favorable actions on lipoprotein metabolism. Consequently, thyromimetic drugs hold promise as lipid-lowering agents if adverse effects can be avoided.This publication has 35 references indexed in Scilit:
- Extended-Release Niacin or Ezetimibe and Carotid Intima–Media ThicknessNew England Journal of Medicine, 2009
- Simvastatin with or without Ezetimibe in Familial HypercholesterolemiaNew England Journal of Medicine, 2008
- Lipoprotein(a) Levels and Risk of Future Coronary Heart DiseaseLarge-Scale Prospective DataArchives of internal medicine (1960), 2008
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Triglycerides and the Risk of Coronary Heart DiseaseCirculation, 2007
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final ReportCirculation, 2002
- ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of StatinsCirculation, 2002
- The Lipid Treatment Assessment Project (L-TAP)Archives of internal medicine (1960), 2000
- Blood Cholesterol Values in Hyperthyroidism and Hypothyroidism — Their SignificanceNew England Journal of Medicine, 1930